Poly Medicure opened lower at ₹1,681.00, compared with its previous close of ₹1,684.30. During today's session, the stock has traded between ₹1,668.00 and ₹1,687.20, with an average traded price of ₹1,678.73. It is currently showing a sideways intraday trend.
An investment of ₹10,000 made 5 years ago in Poly Medicure is now worth
₹ 17,902.00
Giving a profit of
₹ 7,902.00 (79.02%)
Note: Past profits do not guarantee future returns.
Rating by Refinitive from 5 Analysts
Today's Change
-6.00 (-0.36%)
Day High
₹1,687.20
Day Low
₹1,668.00
Day Open
₹1,681.00
Prev Close
₹1,684.30
Volume
9,745
Value Traded
₹1.64 Cr
1W Return
3.96%
1M Return
5.30%
3M Return
-6.04%
6M Return
11.97%
1Y Return
-13.62%
Market Cap (₹ Cr.)
17,011
PE Ratio
53.80
PB Ratio
5.21
Dividend Yield
0.21%
ROE
10.18%
ROCE
13.33%
Book Value (₹)
322.15
Face Value (₹)
5.00
EPS (TTM)
9.38
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
3.96%
6 Weeks
-
1 Month
5.30%
3 Months
-6.04%
9 Months
29.02%
Poly Medicure to host investor meet at Avendus Spark conference on Nov 18
Poly Medicure officials will attend Avendus Spark INDX conference on November 18, 2026. The event will be held in person in Mumbai with one-on-one and group meetings. No unpublished price sensitive information will be disclosed during the meet.
4 days agoPoly Medicure raises standalone EBITDA margin guidance to 26%-27.5% for FY27
Raised standalone EBITDA margin guidance for FY27 to 26%-27.5% from 25%-27%. Consolidated revenue rose 30.8% YoY to ₹580.5 crore in Q2FY27. Reaffirmed consolidated revenue guidance of ₹2,300-2,400 crore for FY27. Europe organic growth surged 39.6% YoY in Q2FY27. Net cash position stands at ₹460 crore as of September 30, 2026.
5 days agoPoly Medicure updates governance and insider trading policies
Poly Medicure updated five governance policies on November 5, 2026. Revisions cover material subsidiary definitions and related party transaction protocols. New codes regulate insider trading and fair disclosure of price-sensitive information. Company Secretary designated as Compliance Officer for oversight.
11 days agoMedicure completes enrollment in MEND-PNPO Phase 3 trial
Medicure completed enrollment of 10 patients in its MEND-PNPO Phase 3 trial. MC-1 holds FDA Orphan Drug, Rare Pediatric Disease, and Fast Track designations. Company eligible for Priority Review Voucher upon NDA approval. Baseline data presented at European Epilepsy Congress; further presentations scheduled.
1mo agoPoly Medicure closes trading window ahead of Q2FY27 results
Trading window closed from October 1, 2026. Closure lasts until 48 hours after Q2FY27 results declaration. Compliance with SEBI insider trading regulations cited. Board meeting date for results to be announced later.
1mo agoPoly Medicure schedules investor meet with Avendus Spark on Sept 30
Poly Medicure Limited to meet Avendus Spark on September 30, 2026. Meeting scheduled for 10:00 am at Ballabgarh plant in Haryana. Interaction is a one-on-one format including a plant visit. No unpublished price sensitive information will be disclosed.
1mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,489.90 | +0.24% | ₹17,169.61 | 120.80 | +84.62% | |
| ₹551.40 | +1.50% | ₹5,604.80 | 79.90 | +60.29% | |
| ₹312.30 | +0.64% | ₹1,661.63 | 221.00 | +30.29% | |
| ₹200.19 | +0.21% | ₹1,101.63 | 33.80 | -35.64% | |
| ₹435.00 | -1.06% | ₹1,014.78 | 18.40 | +26.82% | |
| ₹476.05 | -1.00% | ₹832.78 | 71.00 | -17.88% | |
| ₹350.10 | -5.08% | ₹622.99 | 22.50 | -48.29% | |
| ₹138.71 | +1.20% | ₹616.58 | 17.00 | -43.72% | |
| ₹170.00 | -1.19% | ₹328.74 | 29.10 | +83.78% | |
| ₹301.00 | +0.92% | ₹287.21 | 59.70 | +10.54% | |
| ₹118.10 | -7.45% | ₹224.86 | 47.40 | -62.85% | |
| ₹142.00 | +1.46% | ₹149.29 | 16.40 | -48.36% |
An investment of ₹10,000 made 5 years ago in Poly Medicure is now worth
₹ 17,902.00
Giving a profit of
₹ 7,902.00 (79.02%)
Note: Past profits do not guarantee future returns.